|Articles|February 23, 2022

Sanofi and GSK to Seek Regulatory Authorization for COVID-19 Vaccine

Sanofi and GSK announce they are seeking regulatory authorization for COVID-19 vaccine.

Sanofi and GlaxoSmithKline (GSK) announced on Feb. 23, 2022 that they intend to submit data from both their booster and Phase 3 efficacy trials to support regulatory authorizations applications to FDA and the European Medicines Agency (EMA) for a COVID-19 vaccine.

The Sanofi-GSK vaccine is refrigerator temperature-stable and protein-based. The Sanofi-GSK booster vaccine induced a significant increase in neutralizing antibodies across vaccine platforms and age groups in participants who had already received an authorized mRNA or adenovirus vaccine. When the Sanofi-GSK vaccine was used as a two-dose primary series followed by a booster dose, neutralizing antibodies increased significantly compared to pre-boost levels.

“We’re very pleased with these data, which confirm our strong science and the benefits of our COVID-19 vaccine,” stated Thomas Triomphe, executive vice president of Sanofi Vaccines, in the press release. “The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages. We also observed robust efficacy of the vaccine as a primary series in today’s challenging epidemiological environment. No other global Phase 3 efficacy study has been undertaken during this period with so many variants of concern, including Omicron, and these efficacy data are similar to the recent clinical data from authorized vaccines.”

Source: Sanofi


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.